EVOKE PHARMA, INC. AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT, SERIES B COMMON STOCK PURCHASE WARRANTS, AND SERIES C COMMON STOCK PURCHASE WARRANTSeries A, B, and C Common Stock Purchase Warrant Amendment • September 27th, 2024 • Evoke Pharma Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) is made as of ___________, 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and _____________ (the “Holder”), and constitutes an amendment to that certain Series A Common Stock Purchase Warrant (Warrant No.: A-[ ]), issued by the Company on February 13, 2024 (the “Series A Warrant”) (as amended on March 25, 2024), an amendment to that certain Series B Common Stock Purchase Warrant (Warrant No.: B-[ ]), issued by the Company on February 13, 2024 (the “Series B Warrant”) (as amended on March 25, 2024), and an amendment to that certain Series C Common Stock Purchase Warrant (Warrant No.: C-[ ]), issued by the Company on February 13, 2024 (the “Series C Warrant”) (as amended on March 25, 2024). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings given to such terms in the Series A Warrant, Series B Warrant or the Series C Warrant, as applicable.
EVOKE PHARMA, INC. AMENDMENT TO SERIES C COMMON STOCK PURCHASE WARRANTSeries C Common Stock Purchase Warrant • September 27th, 2024 • Evoke Pharma Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) is made as of ________, 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and _______________ (the “Holder”), and constitutes an amendment to that certain Series C Common Stock Purchase Warrant (Warrant No.: C-[ ]), issued by the Company on February 13, 2024 (the “Series C Warrant”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings given to such terms in the Series C Warrant, as applicable.
